Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data

被引：576
作者：
van der Velden, V. H. J.
Cazzaniga, G.
Schrauder, A.
Hancock, J.
Bader, P.
Panzer-Grumayer, E. R.
Flohr, T.
Sutton, R.
Cave, H.
Madsen, H. O.
Cayuela, J. M.
Trka, J.
Eckert, C.
Foroni, L.
zur Stadt, U.
Beldjord, K.
Raff, T.
van der Schoot, C. E.
van Dongen, J. J. M.
机构：
[1] Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands
[2] Univ Milan, Ctr Ric Tettamanti, Monza, Italy
[3] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany
[4] Univ Bristol, Dept Cellular & Mol Med, Bristol BS8 1TH, Avon, England
[5] Klinikum Johann Wolfgang Goethe Univ, Frankfurt, Germany
[6] Childrens Canc Res Inst, Vienna, Austria
[7] St Anna Childrens Hosp, Vienna, Austria
[8] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany
[9] Univ NSW, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia
[10] Hop Robert Debre, Biochim Genet Lab, F-75019 Paris, France
[11] Rigshosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark
[12] Hop St Louis, Cent Hematol Lab, Paris, France
[13] Charles Univ Prague, Dept Paediat Haematol Oncol, Sch Med 2, Prague, Czech Republic
[14] Charite Med Ctr CVK, Dept Paediat Oncol & Hematol, Berlin, Germany
[15] UCL Royal Free & Univ Coll, Sch Med, Dept Acad Haematol, London, England
[16] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany
[17] Hop Necker Enfants Malad, Hematol Lab, Paris, France
[18] Univ Klinikum Schleswig Holstein, Med Klin 2, Kiel, Germany
[19] Sanquin, Dept Expt Immunohematol, Amsterdam, Netherlands
来源：
LEUKEMIA | 2007年 / 21卷 / 04期
关键词：
MRD; ALL; Ig/; TCR; RQ-PCR; guidelines;
D O I：
10.1038/sj.leu.2404586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs.
引用
收藏
页码：604 / 611
页数：8
相关论文
共 23 条
[1]   Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL [J].
Bader, P ;
Hancock, J ;
Kreyenberg, H ;
Goulden, NJ ;
Niethammer, D ;
Oakhill, A ;
Steward, CG ;
Handgretinger, R ;
Beck, JF ;
Klingebiel, T .
LEUKEMIA, 2002, 16 (09) :1668-1672
[2]   Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia [J].
Brüggemann, M ;
Raff, T ;
Flohr, T ;
Gökbuget, N ;
Nakao, M ;
Droese, J ;
Lüschen, S ;
Pott, C ;
Ritgen, M ;
Scheuring, U ;
Horst, HA ;
Thiel, E ;
Hoelzer, D ;
Bartram, CR ;
Kneba, M .
BLOOD, 2006, 107 (03) :1116-1123
[3]   Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Cavé, H ;
ten Bosch, JV ;
Suciu, S ;
Guidal, C ;
Waterkeyn, C ;
Otten, J ;
Bakkus, M ;
Thielemans, K ;
Grandchamp, B ;
Vilmer, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :591-598
[4]   Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Coustan-Smith, E ;
Sancho, J ;
Hancock, ML ;
Boyett, JM ;
Behm, FG ;
Raimondi, SC ;
Sandlund, JT ;
Rivera, GK ;
Rubnitz, JE ;
Ribeiro, RC ;
Pui, CH ;
Campana, D .
BLOOD, 2000, 96 (08) :2691-2696
[5]   Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia [J].
Eckert, C ;
Biondi, A ;
Seeger, K ;
Cazzaniga, G ;
Hartmann, R ;
Beyermann, B ;
Pogodda, M ;
Proba, J ;
Henze, G .
LANCET, 2001, 358 (9289) :1239-1241
[6]   Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia [J].
Goulden, N ;
Bader, P ;
Van der Velden, V ;
Moppett, J ;
Schilham, M ;
Masden, HO ;
Krejci, O ;
Kreyenberg, H ;
Lankester, A ;
Révész, T ;
Klingebiel, T ;
Van Dongen, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) :24-29
[7]   Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia:: a report of the Pre-BMT MRD Study Group [J].
Krejci, O ;
van der Velden, VHJ ;
Bader, P ;
Kreyenberg, H ;
Goulden, N ;
Hancock, J ;
Schilham, MW ;
Lankester, A ;
Révész, T ;
Klingebiel, T ;
van Dongen, JJM .
BONE MARROW TRANSPLANTATION, 2003, 32 (08) :849-851
[8]   Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia [J].
Marshall, GM ;
Haber, M ;
Kwan, E ;
Zhu, L ;
Ferrara, D ;
Xue, CY ;
Brisco, MJ ;
Sykes, PJ ;
Morley, A ;
Webster, B ;
Dalla Pozza, L ;
Waters, K ;
Norris, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :704-709
[9]   Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin [J].
Moppett, J ;
van der Velden, VHJ ;
Wijkhuijs, AJM ;
Hancock, J ;
van Dongen, JJM ;
Goulden, N .
LEUKEMIA, 2003, 17 (01) :268-270
[10]   Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia [J].
Mortuza, FY ;
Papaioannou, M ;
Moreira, IM ;
Coyle, LA ;
Gameiro, P ;
Gandini, D ;
Prentice, HG ;
Goldstone, A ;
Hoffbrand, AV ;
Foroni, L .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :1094-1104
123